LakeShore Biopharma CoLSBCF ROE % is -43.17% as of Mar. 2025. The stock has 5 warning signs investors should review. Among 1,256 Biotechnology companies, LakeShore Biopharma Co ranks better than 64.09% on this metric.
The historical rank and industry rank for LakeShore Biopharma Co's ROE % or its related term are showing as below:
LSBCF'
s ROE % Range Over the Past 10 Years
Min: -64.38 Med: -41.37 Max: -17.49
Current: -17.49
During the past 5 years, LakeShore Biopharma Co's highest ROE % was -17.49%. The lowest was -64.38%. And the median was -41.37%.
LSBCF's ROE % is ranked better than 64.09% of 1256
companies
in the Biotechnology industry
Industry Median: -38.26
vs LSBCF: -17.49
LakeShore Biopharma Co (OTCPK:LSBCF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2025) net income data. The Revenue data used here is two times the semi-annual (Mar. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, LakeShore Biopharma Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LakeShore Biopharma Co ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's ROE % distribution charts can be found below:
* The bar in red indicates where LakeShore Biopharma Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2025) net income data.
ROE % is displayed in the 30-year financial page.
LakeShore Biopharma Co (LSBCF) has a ROE % of -43.17% as of Mar. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on LakeShore Biopharma Co and its competitors. According to the industry distribution chart, LakeShore Biopharma Co ranks #451 out of 1256 companies in the Biotechnology industry, placing it in the top 35.9%.
Is LakeShore Biopharma Co's ROE % too high?
LakeShore Biopharma Co's current ROE % is -43.17%. Based on the distribution chart, LakeShore Biopharma Co ranks #451 out of 1256 companies in the Biotechnology industry, which is above the industry midpoint.
How does LakeShore Biopharma Co's ROE % compare to ACUT and PPCB?
According to the Biotechnology industry distribution chart, LakeShore Biopharma Co ranks #451 out of 1256 companies for ROE %. This puts LakeShore Biopharma Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on LakeShore Biopharma Co and its competitors. LakeShore Biopharma Co's current ROE % is -43.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LakeShore Biopharma Co stock overvalued right now?
LakeShore Biopharma Co (LSBCF) has a current ROE % of -43.17%. The current ROE % is -43.17%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For LakeShore Biopharma Co (LSBCF), the current ROE % is -43.17% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSBCF has been successfully added to your 